hVIVO Shareholders Back All Resolutions at Annual General Meeting

Open Orphan Plc ( (GB:HVO) ) has provided an update.

hVIVO plc, a global leader in human challenge trials, provides full-service international clinical development support to many of the world’s largest biopharma companies. Its integrated platform covers early preclinical strategy, first-in-human and Phase II/III studies, and advanced virology and immunology lab services from facilities in the UK and Germany.

The company reported that all resolutions proposed at its latest Annual General Meeting were duly passed by shareholders. The smooth approval of AGM resolutions supports continuity in hVIVO’s governance and strategy execution, reinforcing its position as a key partner for accelerating the development of new medicines for its biopharma clients.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £10.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

Spark’s Take on HVO Stock

According to Spark, TipRanks’ AI Analyst, HVO is a Neutral.

The score is held back primarily by the latest financial deterioration (losses, negative gross profit, and significant cash flow weakness). Offsetting this are moderately positive technical momentum signals and earnings-call indications of improving demand/pipeline, though liquidity and booking visibility remain key near-term risks.

To see Spark’s full report on HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world’s ten largest biopharma companies. It operates an end-to-end platform from preclinical strategy through Phase II patient trials and specialist laboratory services, supported by a large participant database and owned sites and labs in the UK and Germany.

With a group heritage of more than a century, hVIVO focuses on accelerating clinical proof-of-concept via four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories. These offerings span expert-led regulatory and clinical strategy, Phase I–III trial execution and recruitment, controlled viral exposure studies in a leading quarantine facility, and advanced virology and immunology lab services, including biobanking and sample storage.

Average Trading Volume: 3,216,178

Technical Sentiment Signal: Sell

Current Market Cap: £51.29M

See more data about HVO stock on TipRanks’ Stock Analysis page.